The '''Cambridge Pulmonary Hypertension Outcome Review''' ('''CAMPHOR''') is a disease specific [[patient-reported outcome]] measure which assesses [[quality of life]] of patients with [[pulmonary hypertension]] (PH).<ref>{{cite journal|last=McKenna|first=Stephen P.|author2=Ratcliffe, Julie|author3= Meads, David M.|author4= Brazier, John E.|title=Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses.|journal=Health and Quality of Life Outcomes|date=21 August 2008|volume=6|issue=65|pages=65|doi=10.1186/1477-7525-6-65|url=http://www.hqlo.com/content/pdf/1477-7525-6-65.pdf|accessdate=2 October 2013|pmid=18718016|pmc=2546377}} {{open access}}</ref> It was the first pulmonary hypertension specific [[questionnaire]] for assessing patient reported symptoms, quality of life and functioning.<ref>{{cite journal|last=Pope|first=Janet|title=Measures of Systemic Sclerosis (Scleroderma)|journal=Arthritis Care & Research|date=November 2011|volume=63|issue=S11|pages=S98–S111|doi=10.1002/acr.20598|pmid=22588774}}</ref>

== History ==

The CAMPHOR questionnaire was developed by Galen Research in 2006<ref>{{cite journal|last=McKenna|first=S.P.|author2=Doughty, N.|author3= Meads, D.M.|author4= Doward, L.C.|author5= Pepke-Zaba, J.|title=The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension|journal=Quality of Life Research|year=2006|volume=15|pages=103–115|doi=10.1007/s11136-005-3513-4|pmid=16411035|issue=1}}</ref> to allow for cost-utility analyses for treatments of PH.<ref>{{cite journal|last=Meads|first=D.M.|author2=McKenna, S.P.|author3= Doughty, N.|author4= Das, C.|author5= Gin-Sing, W.|author6= Langley, J.|author7= Pepke-Zaba, J.|title=The responsiveness and validity of the CAMPHOR Utility Index.|journal=European Respiratory Journal|date=3 September 2008|volume=32|issue=6|pages=1513–1519|doi=10.1183/09031936.00069708|pmid=18768576|doi-access=free}}</ref> The theoretical basis for the CAMPHOR is the needs-based model of quality of life, which states that quality of life is highest when an individual has the ability and capacity to satisfy their own needs.<ref>{{cite journal|last=Hunt|first=Sonja M.|author2=McKenna, Stephen P.|title=The QLDS: A scale for the measurement of quality of life in depression|journal=Health Policy|date=October 1992|volume=22|issue=3|pages=307–319|doi=10.1016/0168-8510(92)90004-U|pmid=10122730}}</ref>

== Properties ==

The CAMPHOR is made up of 3 main dimensions which assess symptoms, functioning and quality of life (QoL).<ref>{{cite journal|last=McKenna|first=Stephen P.|author2=Ratcliffe, Julie|author3= Meads, David M|author4= Brazier, John E.|title=Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses|journal=Health and Quality of Life Outcomes|year=2008|volume=6|issue=65|pages=1–8|doi=10.1186/1477-7525-6-65|pmid=18718016|pmc=2546377}} {{open access}}</ref> The symptom dimension is made up of 25 symptoms and is broken up into 3 subscales: energy, breathlessness and mood.  The QoL scale has 25 items which focus on socialization, role, acceptance, self-esteem, independence, and security. The activity scale has 15 items. Response options include true and not true.  Scores for QoL and symptoms range from 0–25, with higher scores indicating worse quality of life. Activity scores range from 0–30, with higher scores indicating more physical limitations.<ref>{{cite journal|last=Matura|first=Lee Ann|author2=McDonough, Annette|author3= Carroll, Diane L.|title=Health-Related Quality of Life and Psychological States in Patients With Pulmonary Arterial Hypertension|journal=Journal of Cardiovascular Nursing|volume=29|issue=2|date=13 November 2012|pages=178–184|doi=10.1097/JCN.0b013e318275330d|pmid=23151837}}</ref>

== Language Adaptations and Validations ==

Since the development of the CAMPHOR, it has been translated and validated into fourteen different languages,<ref>{{cite web|title=Measures Database|url=http://www.galen-research.com/measures-database/|work=Galen-Research.com|publisher=Galen Research|accessdate=2 October 2013}}</ref> including  Australian and New Zealand English,<ref>{{cite journal|last=Ganderton|first=Louise|author2=Jenkins, Sue|author3= McKenna, Stephen P.|author4= Gain, Kevin|author5= Fowler, Robin|author6= Twiss, James|author7= Gabbay, Eli|title=Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population|journal=Respirology|date=November 2011|volume=16|issue=8|pages=1235–1240|doi=10.1111/j.1440-1843.2011.02030.x|pmid=21810146}}</ref> German<ref>{{cite journal|last=Cima|first=Katharina|author2=Twiss, James|author3= Speich, Rudolf|author4=McKenna, Stephen P.|author5=Grunig, Ekkehard|author6= Kahler, Christian M.|author7= Ehlken, Nicola|author8= Treder, Ursula|author9= Crawford, Sigrid R.|author10= Huber, Lars C.|author11= Ulrich, Silvia|title=The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)|journal=Health and Quality of Life Outcomes|date=September 2012|volume=10|issue=110|pages=110|doi=10.1186/1477-7525-10-110|pmid=22971041|pmc=3492159}} {{open access}}</ref> and Swedish.<ref>{{cite journal|last=Selimovic|first=Nedim|author2=Rundqvist, Bengt|author3= Kjork, Ewa|author4= Viriden, Johan|author5= Twiss, James|author6= McKenna, Stephen P.|title=Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden|journal=Scandinavian Journal of Public Health|date=December 2012|volume=40|issue=8|pages=777–783|doi=10.1177/1403494812464445|pmid=23117210}}</ref>

== Use in Clinical Trials ==

The Cambridge Pulmonary Hypertension Outcome Review has been a useful tool in clinical trials as it allows researchers to assess whether new medication or therapy is effective. The CAMPHOR has been utilized in clinical trials which investigate the effects of [[treprostinil]],<ref>{{cite journal|last=Channick|first=Richard N.|author2=Voswinckel, Robert|author3= Rubin, Lewis J.|title=Inhaled treprostinil: a therapeutic review|journal=Drug Design, Development and Therapy|date=24 January 2012|volume=6|pages=19–28|doi=10.2147/DDDT.S19281|pmc=3267519|pmid=22291467}}</ref><ref>{{cite journal|last=Chen|first=Hubert|author2=Rosenzweig, Erika B.|author3= Gotzkowsky, S Karl|author4= Arneson, Carl|author5= Nelsen, Andrew C.|author6= Bourge, Robert C.|title=Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension|journal=Health and Quality of Life Outcomes|year=2013|volume=11|issue=31|pages=1–8|doi=10.1186/1477-7525-11-31|pmid=23496856|pmc=3610124}} {{open access}}</ref> as well as trials which investigate [[sildenafil]].<ref>{{cite journal|last=Tay|first=Edgar L.W.|author2=Papaphylactou, Maria|author3= Diller, Gerhard Paul|author4= Alonso-Gonzalez, Rafael|author5= Inuzuka, Ryo|author6= Giannakoulas, Georgios|author7= Harries, Carl|author8= Wort, Stephen John|author9= Swan, Lorna|author10= Dimopoulos, Konstantinos|author11= Gatzoulis, Michael A.|title=Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy|journal=International Journal of Cardiology|date=16 June 2011|volume=149|issue=3|pages=372–376|doi=10.1016/j.ijcard.2010.02.020|pmid=20304507}}</ref><ref>{{cite journal|last=Suntharalingam|first=Jay|author2=Treacy, Carmen M.|author3= Doughty, Natalie J.|author4= Goldsmith, Kimberley|author5= Soon, Elaine|author6= Toshner, Mark R.|author7= Sheares, Karen K.|author8= Hughes, Rodney|author9= Morrell, Nicholas W.|author10= Pepke-Zaba, Joanna|title=Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension|journal=Chest|year=2008|volume=134|issue=2|pages=229–236|doi=10.1378/chest.07-2681|url=http://journal.publications.chestnet.org/article.aspx?articleid=1085998|accessdate=2 October 2013|pmid=18263674}}</ref>

== References ==

{{reflist}}

[[Category:Quality of life]]
[[Category:Pulmonary heart disease and diseases of pulmonary circulation]]